GENE ONLINE|News &
Opinion
Blog

2018-05-12|

May 12, 1910: British Biochemist Dorothy Hodgkin Was Born

by GeneOnline
Share To

Dorothy Mary Crowfoot Hodgkin (May 12, 1910 – July 29, 1994) was a British biochemist. Hodgkin began the research in X-ray crystallography during her studies at Somerville College, Oxford. She promoted the use of advanced X-ray crystallography to determine the three-dimensional structure of biological macromolecules. Some of the most influential findings was confirming the structure of penicillin and deciphering structure of vitamin B12. For this she was awarded the 1964 Nobel Prize in Chemistry. In 1969, after 35 years of work and 5 years after receiving the Nobel Prize, she finally deciphered the structure of insulin. X-ray crystallography became a widely used tool in molecular biology, and played a crucial role in determining important structure of many biomolecules later. Dorothy is considered one of the pioneer scientists in the field of X-ray crystallography of biomolecules.

Reference
https://www.nobelprize.org/nobel_prizes/chemistry/laureates/1964/hodgkin-bio.html

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
R&D
Vaccine Development Has No Limits, the Application Direction of mRNA After the Nobel Prize
2023-10-17
R&D
An Updated View on the “Central Dogma” of Molecular Biology
2023-01-03
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top